ESMO Media Releases

Many new anti-cancer medicines add little value for patients compared to standard treatment and are rarely worth the extra cost, according to results of two studies investigating links between clinical benefit and pricing in Europe and the USA, reported at the ESMO Congress 2019.

An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research published in the leading cancer journal Annals of Oncology today.

The European Society for Medical Oncology (ESMO), the leading organisation for medical oncology, has revealed the 2019 winners of its annual awards.

Prof. Eric Van Cutsem has been selected for the 2019 ESMO Award, which will be presented to him at this year’s ESMO Congress taking place in Barcelona, 27 September - 1 October.

Prof. Angelo Di Leo will be presented with the ESMO Lifetime Achievement Award during the Opening Ceremony of the ESMO Congress taking place in Barcelona, 27 September - 1 October.

This year’s ESMO Women for Oncology Award goes to Cristiana Sessa, who will receive the distinction at the ESMO Congress 2019 taking place in Barcelona from 27 September to 1 October

Prof. Charles Swanton is the winner of this year’s ESMO Translational Research Award, which will be presented to him at the upcoming ESMO Congress 2019 in Barcelona.

Participants from all over the world are expected in Barcelona, Spain, between 24 September and 1 October to attend the leading international oncology event in Europe, the ESMO Congress 2019.

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC)

New data have shown for the first time that a combination of targeted therapies can improve survival in patients with advanced bowel cancer. 

Stomach cancer should no longer be considered a disease only of older people, and patients under 40 with chronic digestive symptoms should be more actively investigated – especially if they are of Latin American ethnicity.

Around 3,500 oncology professionals and researchers from around the world will learn about the latest advances in the field at the 21^st ESMO World Congress on Gastrointestinal Cancer taking place in Barcelona, Spain, from 3 to 6 July 2019.